HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究

张小艳; 李清祥; 刘　勇; 李　航; 仇丽娟; 封欣然; 谭立明

doi:10.19401/j.cnki.1007-3639.2021.09.003

您当前的位置：

首页 >

文章列表页 >

HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究

论著 | 更新时间：2025-12-31

- HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究
- A study on the correlation between HMGB1 and clinical characteristics and immune function in patients with breast cancer
- 中国癌症杂志 2021年31卷第9期页码：783-788
- 作者机构：
  
  1. 南昌市第三医院检验科,江西,南昌,330009
  2. 南昌大学第二附属医院检验科,江西,南昌,330006
- 作者简介：
- 基金信息：
  
  江西省科技厅科技计划项目（20171BAB205067）;江西省中医药科研课题（2019A378）。
- DOI：10.19401/j.cnki.1007-3639.2021.09.003
  中图分类号：
- 网络出版：2021-10-08，
  
  纸质出版：2021-10-08
- 稿件说明：
移动端阅览
张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788.

张小艳, 李清祥, 刘　勇, et al. A study on the correlation between HMGB1 and clinical characteristics and immune function in patients with breast cancer[J]. China Oncology, 2021, 31(9): 783-788.
张小艳, 李清祥, 刘　勇, 李　航, 仇丽娟, 封欣然, 谭立明 . HMGB1与乳腺癌患者临床病理学特征及免疫指标的相关性研究[J]. 中国癌症杂志, 2021, 31(9): 783-788. DOI： 10.19401/j.cnki.1007-3639.2021.09.003.

张小艳, 李清祥, 刘　勇, et al. A study on the correlation between HMGB1 and clinical characteristics and immune function in patients with breast cancer[J]. China Oncology, 2021, 31(9): 783-788. DOI： 10.19401/j.cnki.1007-3639.2021.09.003.

摘要

背景与目的：高迁移率族蛋白1（high mobility group box 1，HMGB1）参与DNA复制、转录及翻译过程，与恶性肿瘤的发生、发展、浸润及转移密切相关，并参与炎症、免疫、增殖、转移和自噬等多种信号转导通路的调节。探究HMGB1与乳腺癌患者临床病理学特征、免疫功能及新辅助化疗效果的相关性。方法：选取2019年5月—2020年10月南昌市第三医院收治并接受新辅助化疗的乳腺癌患者120例，采用酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA）测定患者空芯针穿刺活检物中的HMGB1水平，以及调节性T细胞（regulatory T cell，Treg）相关指标IL-10、TGF-β的含量。采用流式细胞术检测CD3

、CD4

、CD8

T淋巴细胞和自然杀伤（natural killer，NK）细胞百分比。采用速率散射比浊法检测免疫球蛋白IgG、IgA、IgM和补体C3、C4的含量。按照95% CI下限水平将研究对象分为高水平组（HMGB1＞ 22.98 ng/mL）和低水平组（HMGB1≤22.98 ng/mL）。新辅助化疗方案的疗程结束后，根据Miller-Payne病理学反应性分级标准评价术后疗效，分析HMGB1水平与疗效的关系。结果：HMGB1与乳腺癌临床分期、淋巴结是否发生转移相关（P ＜ 0.05）；HMGB1与Treg相关指标IL-10、TGF-β显著相关（r=0.734，P ＜ 0.001；r=0.686，P ＜ 0.001）；HMGB1高水平组CD4

T细胞/CD3

T细胞低于低水平组，CD8

T细胞/CD3

T细胞高于低水平组（P ＜ 0.05）；高水平HMGB1患者术后疗效差。结论：HMGB1水平与乳腺癌临床分期、淋巴结转移及细胞免疫功能相关，并有助于预测新辅助化疗的效果。

Abstract

Background and purpose: High mobility group box 1 (HMGB1)

which is involved in the process of DNA replication

transcription and translation

is closely related to the occurrence

dev

elopment

invasion and metastasis of malignant tumors. In addition

HMGB1 is involved in the regulation of various signaling pathways of inflammation

immunity

proliferation

metastasis and autophagy. This research aimed to explore the correlation between HMGB1 and clinicopathological characteristics

immune function and neoadjuvant chemotherapy in patients with breast cancer. Methods: We enrolled a total of 120 breast cancer patients admitted to the Third Hospital of Nanchang from May 2019 to October 2020. The level of HMGB1 in sample of the core needle biopsy was determined by enzyme-linked immunosorbent assay (ELISA). IL-10 and TGF-β as the indicators of regulatory T cell (Treg) were measured. The percentages of CD3

CD4

CD8

T lymphocytes and natural killer (NK) cells were detected by flow cytometry. The contents of immunoglobulin IgG

IgA

IgM and complement C3

C4 were determined by rate-scattering turbidimetry. The study subjects were divided into the high level group (HMGB1 ＞ 22.98 ng/mL) and the low level group (HMGB1≤22.98 ng/mL) according to the lower limit level of the 95% CI. After neoadjuvant chemotherapy

the pathological effect was evaluated according to the Miller-Payne pathological response grading standard. We analyzed the relationship between HMGB1 level and pathological efficacy. Results: HMGB1 levels were associated with breast cancer stage and lymph node metastasis (P ＜ 0.05). The level of HMGB1 was significantly correlated with Treg related IL-10 and TGF-β (r=0.734

P ＜ 0.001; r=0.686

P ＜ 0.001). CD4

T cells/CD3

T cells in the HMGB1 high level group were lower than in the low level group

and CD8

T cells/CD3

T cells were higher in the high level group than in the low level group (P ＜ 0.05). Patients with high-level HMGB1 had worse postoperative effects. Conclusion: The level of HMGB1 is related to breast cancer stage

lymph node metastasis and cellular immune function

and helps predict the effic

acy of neoadjuvant chemotherapy.

关键词

Keywords

references

浏览量

1663

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

多西他赛联合胸腺肽α1对大鼠乳腺癌免疫微环境中Treg数量的影响及其机制研究

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

着丝粒蛋白A驱动的染色体不稳定性与乳腺癌相关性研究的进展及展望：机制、预后及临床靶向治疗应用

中国年轻女性乳腺癌发病、死亡近30年的变迁情况及趋势研究

miR-193a-3p通过靶向TRIM14对乳腺癌干细胞迁移和侵袭的影响